Physician profile
Laura L Bell
NPI 1245894658
$14,735.58
in general payments reported to CMS, 2019-2025
62 companies · $3,488 in 2025
The $3,488 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,336 · 2022: $2,263 · 2023: $2,808 · 2024: $3,840 · 2025: $3,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,019.46 |
| Education | $116.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,781.57 | 2021-2025 | |
| Pfizer INC. | $1,387.53 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $1,225.49 | 2021-2025 | |
| Sk Life Science, INC. | $1,163.28 | 2021-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $930.35 | 2021-2025 | |
| Lilly USA, LLC | $701.87 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Axsome Therapeutics, INC. | $462.20 | 2023-2025 | Sunosi, Symbravo |
| Acorda Therapeutics, INC | $376.17 | 2021-2024 | Inbrija |
| Biogen, INC. | $356.06 | 2021-2024 | Tysabri, Vumerity, Skyclarys |
| Ucb, INC. | $350.95 | 2021-2025 | Nayzilam, Rystiggo, Briviact |
| Amgen INC. | $342.42 | 2021-2025 | Uplizna |
| Lundbeck LLC | $321.63 | 2021-2025 | Vyepti, Rexulti |
| Eisai INC. | $318.39 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $297.10 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $295.78 | 2023-2025 | Rexulti, Nuedexta |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.